JBS Oman Acquisition: US$150 Million Hub Amid EU Setback

Brazil · Companies

JBS Oman acquisition plans are taking shape as the Brazilian meat processing giant commits US$150 million to build a multiprotein hub in the Sultanate, securing an 80% controlling stake in a venture with a state-backed partner. The strategic push into the Middle East, however, coincides with a regulatory headache in Europe, where an official audit has reproved one of the company’s plants and rejected its proposed quality-control fixes.

Inside the Oman Multiprotein Hub

JBS S.A., the world’s largest meat processor by revenue, is making its first direct upstream investment in the Middle East. The company will control 80% of a new food holding company, while Oman Food Capital – an entity linked to the Oman Investment Authority – retains a 20% minority stake.

The deal centers on two key facilities. The A’Namaa poultry plant in Ibri and the Al Bashayer beef and lamb facility in Thumrait will form the backbone of a halal-certified production platform. JBS expects the combined operation to reach a capacity of 300,000 metric tons per year.

Daily throughput targets are ambitious. The plans call for processing roughly 1,000 head of cattle, 5,000 lambs, and 600,000 chickens every day once fully operational. JBS projects the venture will create around 3,000 local jobs.

Timelines are tight. Beef and lamb production could start within six months, subject to final regulatory approvals. Poultry operations are expected to follow within twelve months, positioning Oman as an export springboard for the Gulf Cooperation Council and North African markets.

JBS: A Global Protein Powerhouse

For foreign investors and expatriates unfamiliar with the name, JBS is a Brazil-based multinational that has grown from a small slaughterhouse in Anápolis to the largest protein producer on the planet. It operates across beef, poultry, pork, and lamb supply chains, with processing units in the Americas, Europe, Australia, and Asia.

The company is already a familiar name on capital markets. JBS completed its long-awaited secondary listing on the New York Stock Exchange (NYSE) in June 2025, trading under the ticker JBS. This dual-listing structure, alongside its São Paulo B3 listing, gave U.S. investors direct access to the stock.

Any recent speculation about a “new” U.S. listing in July 2026 likely refers to routine capital-markets maintenance or a specific filing rather than a fresh IPO or exchange debut. The NYSE presence is already established, and no additional listing step has been confirmed in the available documentation.

The Oman move fits a broader pattern. JBS has consistently used acquisitions and greenfield projects to diversify its geographic footprint, reducing exposure to trade barriers and currency volatility in its home market.

Live Company IntelligenceJBS N.V. — the full investor dossier

Wall Street view

1Buy

0Hold

0Sell

$18.82· +30% vs 200-day

Valuation & profitability

Price & risk

$11.4552-wk high

$17.27

Revenue trend · 6y

$471.14B

Ownership

Dividend

What JBS N.V. does.JBS N.V., together with its subsidiaries, engages in the processing of animal proteins, encompassing activities related to beef, pork, lamb, and poultry worldwide. The company is involved in the production and marketing of prepared foods and other related products, as well as operations in leather, collagen, hygiene and beauty products, metal packaging,…

The EU Audit Setback

While JBS expands in the Gulf, it faces a compliance challenge in Europe. An audit conducted by the European Commission’s Directorate-General for Health and Food Safety (DG-SANTE) has reproved a JBS facility, according to reports citing the findings.

The audit did not merely flag deficiencies. It went a step further by formally rejecting the corrective action plan that JBS submitted to address the problems. Such a rejection is a serious regulatory signal, indicating that the proposed fixes were deemed insufficient to meet European Union food-safety standards.

The specific plant name and location were not identified in the available research materials. Without the full audit text, the precise nature of the non-compliance – whether related to hygiene, traceability, or residue controls – remains unconfirmed.

The practical implications are significant. A rejected corrective plan typically means the establishment in question cannot freely export to the EU market. Shipments may remain blocked, delayed, or placed under heightened scrutiny until authorities accept a revised and fully implemented quality-control program.

For JBS, the EU is a high-value destination. Any prolonged restriction on a plant’s export license can shift trade flows and pressure margins in the affected division.

Strategic Calculus: Growth vs. Compliance

The contrasting headlines capture the dual reality of running a global protein empire. The Oman investment signals confidence in long-term demand for halal protein across the Middle East and North Africa, a region with fast-growing populations and rising meat consumption.

The US$150 million outlay is modest relative to JBS’s annual revenue, which exceeded R$375 billion (~US$73.5 billion) in recent fiscal years. But the strategic value lies in establishing a local production base that bypasses logistical bottlenecks and tariff barriers.

Simultaneously, the EU audit underscores the relentless regulatory pressure facing meat exporters. European authorities have tightened controls on Brazilian meat shipments in past years, and a rejected corrective plan suggests the scrutiny is not easing.

Investors will watch for two things: how quickly JBS can get the Omani plants running and whether it can resolve the EU compliance gap before it affects quarterly export volumes.

What Comes Next

In Oman, the immediate priority is completing the regulatory approvals needed to start beef and lamb production within the six-month window. Poultry output, with its longer lead time, will follow as the A’Namaa plant ramps up.

On the EU front, JBS will need to submit a revised corrective action plan that satisfies DG-SANTE inspectors. The timeline for re-approval is uncertain and depends on the complexity of the deficiencies identified.

Neither development alters JBS’s fundamental position as the dominant force in global meat processing. But together, they illustrate the balancing act required when a company operates across dozens of regulatory jurisdictions simultaneously.

Frequently Asked Questions

What is the JBS Oman acquisition?

It is a US$150 million investment by Brazil-based JBS to acquire an 80% stake in a food holding company in Oman, partnering with Oman Food Capital (20%). The venture will operate poultry, beef, and lamb processing plants in Ibri and Thumrait.

Is JBS planning a new U.S. stock listing in 2026?

No new listing has been confirmed. JBS already completed its dual listing on the New York Stock Exchange (NYSE) in June 2025. Any recent references to a U.S. listing likely involve routine filings rather than a fresh IPO.

What happened with the EU audit of JBS?

An EU DG-SANTE audit reproved a JBS plant and rejected its proposed corrective quality-control plan. The specific facility was not named in available sources, but the rejection typically means exports from that plant to the EU face restrictions until deficiencies are resolved.

Sources & Further Reading

LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.